Fennec Pharmaceuticals Inc (FENC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $410.25M
Last updated: Nov 17, 2026 at 4:42 PM ET
Fennec Pharmaceuticals Inc (FENC) Statistics
Fennec Pharmaceuticals (FENC) has a market cap of $410.25M and an enterprise value of $361.56M. Its share count is up 25.90% from a year earlier. Revenue grew 71.09% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 11.87% below the market cap, as cash exceeds debt.
| Market Cap | $410.25M |
|---|---|
| Enterprise Value | $361.56M |
| Latest price (Nov 17, 2026) | $13.58 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.2x and 9.7x.
| P/E Ratio | 169.8x |
|---|---|
| Forward P/E | 47.0x |
| P/S Ratio | 7.2x |
| Forward P/S | 5.5x |
| P/B Ratio | 9.7x |
| P/OCF Ratio | 130.3x |
Enterprise Valuation
Counting debt and cash, the company is valued at 109.5x EBITDA.
| EV / Earnings | 178.3x |
|---|---|
| EV / Sales | 5.4x |
| EV / EBITDA | 109.5x |
| EV / EBIT | 97.7x |
Price Statistics
The stock is up 72.77% over 52 weeks and trades 27.27% above its 50-day average.
| Beta (1Y) | 1.41 |
|---|---|
| 52-Week Change | +72.77% |
| 1-Month Change | +32.23% |
| 3-Month Change | +14.41% |
| 6-Month Change | +39.14% |
| 5-Year Change | +10.58% |
| 10-Year Change | +409.45% |
| Total Return (1Y) | +72.77% |
| Total Return (3Y CAGR) | +17.74% |
| Total Return (5Y CAGR) | +6.64% |
| Return vs SPY (1Y) | +43.64% |
| Max Drawdown (1Y) | -35.82% |
| Max Drawdown (3Y) | -65.63% |
| Sharpe Ratio (1Y) | 0.67 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $10.67 |
| 200-Day Average | $9.41 |
| 52-Week Range | $5.65 to $13.25 |
| RSI (14 Days) | 72.8 |
| Average Volume (20 Days) | 247.82K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.11x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.11x |
|---|---|
| Quick Ratio | 5.95x |
| Debt / Equity | 0.00x |
| Interest Coverage | 1.56x |
Returns and Efficiency
Return on equity is 4.12% and return on assets is 2.43% over the last 12 months.
| Return on Equity (ROE) | 4.12% |
|---|---|
| Return on Assets (ROA) | 2.43% |
| Return on Capital Employed (ROCE) | 5.27% |
| ROA (5Y Average) | -47.98% |
| ROIC (5Y Average) | 110.03% |
| Asset Turnover | 1.00x |
| Inventory Turnover | 1.73x |
| Receivables Turnover | 2.82x |
| Cash Conversion Cycle | -135 days |
Taxes
Income tax took 16.21% of pretax income over the last 12 months.
| Income Tax (TTM) | $374.00K |
|---|---|
| Effective Tax Rate | 16.21% |
Scores
FENC has an Altman Z-Score of 6.51, in the safe zone above 2.99, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 6.51 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 0 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $66.37M over the last 12 months.
| Revenue | $66.37M |
|---|---|
| Revenue Growth (YoY) | +71.09% |
| Gross Profit | $62.47M |
| Operating Income | $3.72M |
| Pretax Income | $2.31M |
| Net Income | $2.03M |
| EBITDA | $3.91M |
| EBIT | $3.70M |
| Reported EPS (TTM) | $0.08 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 58.88% of the $83.54M in total assets.
| Cash and Equivalents | $48.68M |
|---|---|
| Total Debt | $0 |
| Net Cash | $48.68M |
| Net Cash Per Share | $1.39 |
| Working Capital | $67.71M |
| Shareholder Equity | $49.19M |
| Book Value Per Share | $1.40 |
| Total Assets | $83.54M |
| Total Liabilities | $34.35M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $3.15M |
|---|---|
| FCF Per Share | $0.09 |
| Depreciation and Amortization | $207.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 5.60%.
| Gross Margin | 94.13% |
|---|---|
| Operating Margin | 5.60% |
| Pretax Margin | 3.48% |
| Net Margin | 3.06% |
| EBITDA Margin | 5.89% |
| EBIT Margin | 5.58% |
Growth
Revenue grew 207.52% a year over 3 years.
| Revenue Growth (3Y CAGR) | +207.52% |
|---|---|
| Revenue Growth (5Y CAGR) | +204.69% |
Dividends and Yields
FENC does not pay a dividend.
| Earnings Yield | 0.59% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 7 similar companies, FENC has the 4th highest P/S.
P/S RatioPeer median 4.3x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -27.97%
| P/S Ratio | 7.2x vs 4.3x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +71.09% vs -27.97% median |
Analyst Forecast
Consensus estimates put revenue growth at 53.64% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +53.64% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About FENC
What is FENC's market cap?
Fennec Pharmaceuticals has a market cap of $410.25M. Its enterprise value, which adds debt and subtracts cash, is $361.56M.
What is FENC's P/E ratio?
Fennec Pharmaceuticals has a trailing P/E ratio of 169.8x and a forward P/E of 47.0x.
How many shares of FENC are outstanding?
Fennec Pharmaceuticals has 35.11M shares outstanding. The count is up 25.90% from a year earlier.
Does FENC pay a dividend?
No. Fennec Pharmaceuticals does not pay a dividend.
How much debt does FENC have?
Fennec Pharmaceuticals has $0 of total debt and $48.68M of cash and equivalents, a net cash position of $48.68M.
FENC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors